Sector News

Ansell to buy UK-based protective clothing maker Microgard

April 1, 2015
Life sciences
Glove and condom maker Ansell Limited will acquire UK-based protective clothing manufacturer Microgard for £59 million ($A113m).
 
Microgard has sales in more than 75 countries, a manufacturing facility in Xiamen, China and about 750 employees worldwide.
 
The company has grown rapidly, mainly in Europe, the Middle East and Africa, and in the Asia-Pacific region, with sales of about $US40m during calendar year 2014, Ansell said in a statement today.
 
Ansell (ANN) chief executive Magnus Nicolin said the acquisition was a critical step in building the company’s body protection operations, as part of its Industrial Global Business unit.
 
“Together with our current chemical protective glove range, we now have a world-class portfolio of chemical protection solutions, leveraging our strong global footprint,” he said.
 
Microgard supplies customers in the industrial, chemical, oil and gas and life science sectors and Mr Nicolin said the purchase would complement previous acquisitions that had expanded Ansell’s product range.
 
Ansell expects the acquisition, including all transaction costs, to be marginally dilutive to earnings per share in fiscal 2015 and to be accretive in fiscal 2016.
 
The purchase price is equivalent to a multiple of about nine times on trailing 12-months adjusted earnings before interest, tax, depreciation and amortisation, according to the company.
 
The deal is subject to German antitrust clearance and is expected to complete during the second quarter of the current calendar year.
 

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).